An increase in symptoms of<unk>  has been observed to correspond with decreasing levels of<unk>  in menopausal women. This observation has led researchers to propose a link between<unk>  and<unk> . While the first onset of<unk>  generally occurs between the ages of 20-25 for men, first onset occurs approximately 5 years later for women, with a second peak (late onset<unk>  between the ages of 40 to 45. Animal studies suggest that<unk>  acts as a barrier to dopamine receptors, and so may prevent the increase in dopamine found in patients with<unk> . However, in contradictory studies,<unk>  either increased or decreased dopamine receptors, depending on the duration of the experiment. When<unk>  levels are low, women are more susceptible and respond poorly to anti-psychotic drugs. Consequently<unk>  is often used to treat<unk>  in women. Studies show that<unk>  patches can reduce the positive symptoms of<unk>  (at least in the short term). Researchers believe that<unk>  could also be used to treat this disease in men.
Effects of estrogen on schizophrenia
Sex differences in schizophrenia
Psychological effects of Internet use
Impact of alcohol on aging
Management of borderline personality disorder
Management of schizophrenia
Epigenetics of anxiety and stress–related disorders
Epigenetics of schizophrenia